Insights provides context and perspective about key pharmacy trends and issues

Drug Pipeline
Breakthrough Therapies and New Biologics Feature in the Gene Therapy Pipeline More
Briefing
Speciality Pharmacy Pipeline Drugs to Watch | Q4 2021 - Q1 2022
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q4 2021 - Q1 2022 More
Specialty Report
Drug Pipeline
... More
Briefing
Drug Pipeline
The gene therapy pipeline report highlights what payors can expect for a variety of conditions. More
Briefing
Drug Pipeline
Biosimilars help to increase market competition. Balancing the use of biosimilars and biologics with strategic formulary decisions deliver lower costs. More
Briefing
Speciality Pharmacy Pipeline Drugs to Watch | Q3 - Q4 2021
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q3 - Q4 2021 More
Specialty Report
Near-Term Outlook for Projected Gene Therapies and Their Approval Timelines | Payor Solutions
Drug Pipeline
Projected Approvals of Pipeline Gene Therapies Expected to Treat Conditions with Few Options More
Briefing
Drug Pipeline
Effective management strategies can help payors manage cost for a range of new treatment options in the drug pipeline. Several medications are nearing approvals for Alzheimer’s, oncology... More
Briefing
Speciality Pharmacy Pipeline Drugs to Watch | Q2 - Q3 2021
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q1 - Q2 2021 More
Specialty Report
Pipeline Therapies Could Expand Choices for Conditions with Limited Options | Payor Solutions | CVS Health
Drug Pipeline
Our periodic gene therapy report helps payor better understand the potential for these innovative treatments to transform patient care and outcomes More
Briefing